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The content of this supplement is based on the
educational symposium entitled ‘‘Staphylococcal
infections – whatever next?’’ which took place at the
15th European Congress of Clinical Microbiology
and Infectious Diseases (ECCMID) in Copenha-
gen, April 2005.
Staphylococcus aureus is an important cause of
serious infections both in hospitals and the com-
munity. This pathogen has overcome almost
every attempt to combat it; resistance to a range
of antibiotics is widespread among clinical iso-
lates, and methicillin-resistant S. aureus (MRSA) is
an increasingly common finding. In the last few
years, resistance to the conventional first-line
agents for MRSA infections, the glycopeptides,
has become a worrying reality; the emergence of
vancomycin-intermediate strains has been closely
followed by a still limited number of fully
vancomycin-resistant isolates. At the same time,
evidence is building that MRSA is becoming more
prevalent, not only in healthcare settings but also
within the community – a development that
threatens to impact significantly on efforts to
control this important pathogen. There is thus a
pressing need for new agents to treat S. aureus
infections, and new drugs, such as the cyclic
lipopeptide daptomycin, are welcome additions.
This supplement provides a timely analysis of the
key issues facing clinicians today, and looks at
possible future developments in the battle with
this important pathogen.
Professor Gian Carlo Schito sets the scene by
briefly reinforcing the importance ofS. aureus as the
cause of serious infections.Hediscusses the history
of the development of antibiotic therapy,
and reviews the molecular mechanisms by which
S. aureus has acquired resistance to many currently
available agents. The increasingly widespread use
of antibiotics provides the potential for selection of
resistant strains through the acquisition of resist-
ance genes. Indeed, multidrug-resistant strains of
S. aureus are now commonplace across Europe,
though the incidence varies significantly among
countries. The glycopeptide vancomycin has been
considered the mainstay of treatment for drug-
resistant S. aureus strains for more than 40 years.
However, resistance to this antibiotic has now
emerged and emphasises the need for new therap-
ies for drug-resistant S. aureus infections.
Dr Marjolein Kluytmans-VandenBergh and
Dr Jan Kluytmans highlight the emerging prob-
lem of community-acquired MRSA (CA-MRSA).
Once confined to the hospital environment,
MRSA is now emerging as a cause of serious
infections in the community. To date, the preval-
ence of CA-MRSA has been difficult to determine
in studies as several definitions of CA-MRSA
have been employed. Molecular epidemiological
definitions are currently considered to be the most
effective method of distinguishing CA-MRSA
from hospital-acquired MRSA. The authors also
focus on the risk of CA-MRSA strains spreading
into hospitals; mathematical models suggest CA-
MRSA has the potential to become endemic in
both the community and hospital settings. Con-
sequently, the need for measures to contain CA-
MRSA is considered to be a matter of urgency.
In the third article, Professor Peter Appelbaum
discusses the emergence of vancomycin-interme-
diate and vancomycin-resistant S. aureus strains
(VISA and VRSA, respectively) and their impact
in the clinical setting. Vancomycin-intermediate
isolates were first identified in Japan in 1997 and,
more recently, four vancomycin-resistant strains
have been identified in the USA. The emergence
of such organisms is of considerable concern.
Although the precise mechanism of vancomycin
resistance has not been determined, a number of
studies suggest that thickening of the bacterial cell
wall, in addition to other structural and/or
metabolic changes involving the cell wall, plays
a key role. Directed screening of patients with
suspected vancomycin resistance will assist us in
establishing the extent of the problem, and be
integral to helping us to devise measures to
contain it.
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The articles in this supplement all emphasise
the need for the development of new classes of
antimicrobial agents to combat Gram-positive,
notably S. aureus, infections. Professor Michael
Rybak discusses the development of daptomycin,
the first in a new class of antibiotics, the cyclic
lipopeptides. Daptomycin has a novel mechanism
of action, causing depolarisation of the cell mem-
brane, and resulting in bacterial cell death due to
widespread disruption of macromolecular syn-
thesis. It is rapidly bactericidal against Gram-
positive pathogens, including staphylococci and
enterococci. No antagonism has been seen
between daptomycin and other antibiotics.
In-vitro studies have shown that it is difficult to
generate daptomycin-resistant isolates, and the
incidence of cross-resistance with existing agents
is likely to be low. Daptomycin is indicated in the
USA for the treatment of Gram-positive compli-
cated skin and soft tissue infections, and is
currently undergoing review by the European
Medicines Evaluation Agency (EMEA).
The emergence of resistant S. aureus strains is of
major clinical concern, and there is an urgent need
both for the development of better practice in the
use of existing antibiotics, and for novel therapies
to treat resistant infections. I hope that the follow-
ing articles will stimulate further consideration
and discussion of possible approaches by which to
address the increasing problem of drug-resistant
pathogens.
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